CIBERDEM, ISCIII, Madrid, Spain.
UGC Endocrinología y Nutrición. Hospital Regional Universitario de Málaga. IBIMA Plataforma BIONAND, Málaga, Spain.
Int J Obes (Lond). 2022 Nov;46(11):2013-2020. doi: 10.1038/s41366-022-01212-1. Epub 2022 Aug 20.
BACKGROUND/OBJECTIVES: Although vascular endothelial growth factor b (VEGFb) might have an impact on the development of obesity, diabetes and related disorders, the possible relationship between VEGFb serum levels and the incidence of these metabolic complications in humans is still unknown. The aim of our study was to evaluate the association between VEGFb serum levels and the new-onset of metabolic syndrome (MS) and its components in the Spanish adult population after 7.5 years of follow-up.
SUBJECTS/METHODS: A total of 908 subjects from the Di@bet.es cohort study without MS at cross-sectional stage according to International Diabetes Federation (IDF) or Adult Treatment Panel III (ATP-III) criteria were included. Additionally, five sub-populations were grouped according to the absence of each MS component at baseline. Socio-demographic, anthropometric and clinical data were recorded. The Short Form of International Physical Activity Questionnaire (SF-IPAQ) was used to estimate physical activity. A fasting blood extraction and an oral glucose tolerance test were performed. Serum determinations of glucose, lipids, hsCRP and insulin were made. VEGFb levels were determined and categorized according to the 75th percentile of the variable. New cases of MS and its components were defined according to ATPIII and IDF criteria.
A total of 181 or 146 people developed MS defined by IDF or ATP-III criteria respectively. Serum triglyceride levels, hs-CRP and systolic blood pressure at the baseline study were significantly different according to the VEGFb categories. Adjusted logistic regression analysis showed that the likelihood of developing MS and abdominal obesity was statistically reduced in subjects included in the higher VEGFb category.
Low serum levels of VEGFb may be considered as early indicators of incident MS and abdominal obesity in the Spanish adult population free of MS, independently of other important predictor variables.
背景/目的：尽管血管内皮生长因子 b（VEGFb）可能对肥胖、糖尿病和相关疾病的发展产生影响，但 VEGFb 血清水平与这些代谢并发症在人类中的发生之间的可能关系尚不清楚。我们的研究目的是评估 VEGFb 血清水平与西班牙成年人人群中代谢综合征（MS）及其组分的新发之间的关联，随访时间为 7.5 年。
受试者/方法：共纳入 908 名受试者，他们来自 Di@bet.es 队列研究，在横断面阶段根据国际糖尿病联合会（IDF）或成人治疗小组 III（ATP-III）标准无 MS。此外，根据基线时每个 MS 组分的缺失情况将五个亚组分组。记录社会人口统计学、人体测量学和临床数据。使用国际体力活动短问卷（SF-IPAQ）估计体力活动。进行空腹血液提取和口服葡萄糖耐量试验。测定血清葡萄糖、脂质、hsCRP 和胰岛素。根据变量的第 75 百分位数确定 VEGFb 水平并进行分类。根据 ATPIII 和 IDF 标准定义新发 MS 及其组分。
共有 181 人或 146 人根据 IDF 或 ATP-III 标准分别发展为 MS。基线研究时血清三酰甘油水平、hs-CRP 和收缩压根据 VEGFb 类别存在显著差异。调整后的逻辑回归分析表明，在较高 VEGFb 类别的受试者中，MS 和腹型肥胖的发生可能性具有统计学意义降低。
在无 MS 的西班牙成年人群中，低血清 VEGFb 水平可能被视为 MS 和腹型肥胖的早期指标，独立于其他重要预测变量。
